NCT01362322View on ClinicalTrials.gov

Immunogenicity and Safety of BoostrixTM Using a New Syringe in 10 to 15-year Old Adolescents

PHASE4CompletedINTERVENTIONAL
Enrollment

671

Participants

Timeline

Start Date

July 1, 2011

Primary Completion Date

September 3, 2012

Study Completion Date

September 3, 2012

Conditions
DiphtheriaTetanusAcellular Pertussis
Interventions
BIOLOGICAL

Boostrix TM (new syringe presentation)

Single dose, intramuscular administration in a new syringe presentation

BIOLOGICAL

Boostrix TM (previous syringe presentation)

Single dose, intramuscular administration in previous syringe presentation

Trial Locations (3)

55075

GSK Investigational Site, Estado de México

64460

GSK Investigational Site, Monterrey

Unknown

GSK Investigational Site, Santiago

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01362322 - Immunogenicity and Safety of BoostrixTM Using a New Syringe in 10 to 15-year Old Adolescents | Biotech Hunter | Biotech Hunter